A Phase 3, Double-Blind, Multicenter, Randomized, Placebo Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome�) for the Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving R
Read time: 1 mins
Last updated:16th Nov 2010
To determine the prophylactic efficacy of AmBisome compared to placebo in preventing IFIs in subjects with ALL undergoing remission-induction chemotherapy.
|Study start date||2010-11-16|